|
BROMOCRIPTINE MAY INCREASE PLASMA LEVEL OF THE OTHER DRUG
|
ALCOHOL REDUCES TOLERANCE TO BROMOCRIPTINE AND VICE- VERSA
|
ALCOHOL REDUCES TOLERANCE TO BROMOCRIPTINE AND VICE- VERSA
|
ALCOHOL REDUCES TOLERANCE TO BROMOCRIPTINE AND VICE- VERSA
|
ALCOHOL REDUCES TOLERANCE TO BROMOCRIPTINE AND VICE- VERSA
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CYCLOSPORINE PLASMA LEVELS ARE INCREASED BY THE DRUG
|
|
ZIPRASIDONE INHIBITS THE EFFECT OF OTHER DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
TAMOXIFEN SERUM LEVELS ARE RAISED WITH INCREASED RISK OF THROMBO-EMBOLIC EVENTS WITH CONCURRENT ADMINISTRATION OF OTHER ANTI-NEOPLASTIC AGENTS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
CO-ADMINISTRATION CAN CAUSE HYPERTENSIVE CRISIS
|
TACROLIMUS SERUM CONCENTRATION IS INCREASED BY CONCOMITANT USE
|
OCTREOTIDE INCREASES BIOAVAILABILITY OF THE DRUG
|
OCTREOTIDE INCREASES BIOAVAILABILITY OF THE DRUG
|
BROMOCRIPTINE EFFICACY IS REDUCED ON CONCOMITANT USE
|
BROMOCRIPTINE EFFICACY IS REDUCED ON CONCOMITANT USE
|
BROMOCRIPTINE EFFICACY IS REDUCED ON CONCOMITANT USE
|